Take action against Alzheimer’s

Do you want to take action against Alzheimer’s, just like me? See below the full overview of our studies.

What we’ve achieved so far

75+

Trials

250+

Participants

3

Locations

Our Alzheimer’s trials

Filter

All trialsAlzheimer

Green Memory

The goal of this research is to find out how safe and effective the new drug Green Memory (GV971-007) is for the treatment of participants with early-stage Alzheimer's (mild cognitive impairment and mild dementia caused by Alzheimer's). We compare the effect of the new drug Green Memory with the effect of a placebo (drug without an active ingredient, a 'fake drug'). The study drug is administered through an IV.

audience50 - 85 years (M/F)

levelEarly stage of Alzheimer's

duration86 weeks

locationAmsterdam, Den Bosch, and Zwolle

All trialsAlzheimer

Autonomy

A phase II, double-blind, randomized, placebo-controlled study, parallel-group, multicenter research on the safety and effectiveness of JNJ-63733657. A monoclonal anti-tau-antibody, to be tested with participants in the early stages of Alzheimer’s disease.

audience55 - 80 years (M/F)

levelEarly stage of Alzheimer's

duration4.5 years

locationAmsterdam, Den Bosch and Zwolle

All trialsAlzheimer

Alector AD

A phase II, multicentre, double-blind, randomized, placebo-controlled study of the safety and efficacy of the drug AL002 in participants with mild to moderate Alzheimer's disease.

audience50 - 85 years (M / F)

levelDementia due to Alzheimer's disease

duration112 weeks

locationAmsterdam, Den Bosch and Zwolle

All trialsAlzheimer

Open Road

An open-label, multicenter, follow-up study to evaluate the safety and tolerability of long-term administration of Gantenerumab in subjects with Alzheimer's disease.

audience50 - 85 years (M/F)

levelDementia due to Alzheimer's disease

duration2 years

locationAmsterdam

All trialsAlzheimer

Embark

Phase IIIb, open-label, multicenter safety study of BIIB037 (aducanumab) in study participants with Alzheimer's disease who previously participated in the aducanumab studies: 221AD103, 221AD301, 221AD302, and 221AD205.

audience50 - 85 years (M / F)

levelDementia due to Alzheimer's disease

duration2,5 years

locationAmsterdam

All trialsAlzheimer

Alector FTD

A multicenter, open-label phase II study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL001 in heterozygous carriers of C9orf72 mutations leading to frontotemporal dementia.

audience18 - 85 years (M / F)

levelGenetically confirmed C9orf72 mutation

duration112 weeks

locationAmsterdam

All trialsAlzheimer

Trailblazer

A phase II, double-blind, randomized, placebo-controlled trial of the safety, tolerability and effectiveness of Donanemab in early-stage Alzheimer's disease.

audience60 - 85 years (M / F)

levelMild Cognitive Impairment (MCI) due to Alzheimer's, mild-stage Alzheimer's

duration2.5 years

locationAmsterdam, Den Bosch and Zwolle

All trialsAlzheimer

Viviad

A phase IIb trial, multicenter, randomized, double-blind, placebo-controlled study of the safety, tolerability and efficacy of the drug PQ912 in participants with mild to moderate Alzheimer's disease.

audience50 - 80 years (M / F)

levelMild Cognitive Impairment (MCI) due to Alzheimer's, mild-stage Alzheimer's

duration48-96 weeks

locationAmsterdam

All trialsAlzheimer

Alzheon Phase II

A phase II, multicenter, study of the effects of the research drug ALZ-801 on biomarkers involved in the progression of Alzheimer's disease.

audience50 - 80 years (M / F)

levelMild Cognitive Impairment (MCI) due to Alzheimer's, light-stage Alzheimer's and carrier of APOE e4 gene.

durationAbout 2 years

locationAmsterdam, Den Bosch and Zwolle

Let us know how we can help you

Do you have any questions or would you like to know more about one of our studies? Contact us by phone or email. We are happy to help you.

What do our participants say?

“The most important thing is that there is a solution.”

“With my participation, I may also help others,” says Mr. Arts, one of our participants.

Our partners

Our mission is to eliminate brain diseases, but we cannot do that alone. That is why we work together with leading partners.